EAST HANOVER, N.J., Aug. 19 /PRNewswire/ -- Newly published data in The New England Journal of Medicine affirm five-year upfront use of Femara((R)) (letrozole tablets) following surgery as an optimal treatment approach versus tamoxifen for postmenopausal women with early stage breast cancer (hormone-receptor positive).
